Advaxis Inc (ADXS)

11.80
0.01 0.08
NASDAQ : Health Care
Prev Close 11.81
Open 11.81
Day Low/High 11.72 / 12.23
52 Wk Low/High 5.21 / 22.20
Volume 513.36K
Avg Volume 1.12M
Exchange NASDAQ
Shares Outstanding 34.35M
Market Cap 406.32M
EPS -1.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Think Big on These Small Biotechs

Think Big on These Small Biotechs

New drugs give small-cap companies opportunity to expand markets and revenues.

Don't Roll the Dice on Central Bank News

Don't Roll the Dice on Central Bank News

The bears are trying it out on the Bank of England news today, but they may get squeezed.

Amgen, Regeneron Forge New, Separate Cancer Immunotherapy Pacts

Amgen, Regeneron Forge New, Separate Cancer Immunotherapy Pacts

The new deals signal a long-term commitment from two of the largest biotech companies to focus on cancer immunotherapy as a platform for future growth.

Amgen And Advaxis Enter Global Cancer Immunotherapies Collaboration

Amgen And Advaxis Enter Global Cancer Immunotherapies Collaboration

Collaboration Will Advance Highly Targeted, Patient-Specific Treatment Approach

Aduro Biotech Pancreatic Cancer Immunotherapy Fails Mid-Stage Study

Aduro Biotech Pancreatic Cancer Immunotherapy Fails Mid-Stage Study

A type of common bacteria re-engineered by Aduro Biotech to engage the immune system to kill pancreatic cancer failed a mid-stage study, the company announced Monday.

These 5 Stocks Are Poised for Breakouts

These 5 Stocks Are Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

Late Breaking Data At AACR Annual Meeting From Advaxis Phase 2 Study Of AXAL Highlights Potential Of The Company's Lm Technology™ Platform

Late Breaking Data At AACR Annual Meeting From Advaxis Phase 2 Study Of AXAL Highlights Potential Of The Company's Lm Technology™ Platform

First clinical data with AXAL to show evidence of cytotoxic T cell infiltration into the tumor immune microenvironment or TME for HPV-Positive oropharyngeal cancer

UPDATE -- Advaxis Hosts Research Reception To Review Late-Breaking AACR Abstract

UPDATE -- Advaxis Hosts Research Reception To Review Late-Breaking AACR Abstract

Researchers to Provide Updates on Evidence of Impact of Lm Immunotherapy in the Tumor Microenvironment